Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMOSTXF)

Drug Name

Rigosertib Drug Info

Synonyms

Rigosertib; 592542-59-1; UNII-67DOW7F9GL; 67DOW7F9GL; N-[2-Methoxy-5-({[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine; ON-01910.Na; Rigosertib [USAN:INN]; 6FS; Rigosertib (USAN); AC1OCFT5; SCHEMBL498624; Estybon (proposed trade name); SCHEMBL498623; GTPL7833; CHEMBL1241855; ON01910.Na; DTXSID30207984; CHEBI:124939; OWBFCJROIKNMGD-BQYQJAHWSA-N; 1910 Na; ZINC3942646; BCP08296; BDBM50060917; 4006AH; AKOS015966442; DB12146; SB16468; (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic a

Indication

Disease Entry	ICD 11	Status	REF
Myelodysplastic syndrome	2A37	Phase 3	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 3	[2]

Cross-matching ID

PubChem CID: 6918736
ChEBI ID: CHEBI:124939
CAS Number: CAS 592542-59-1
TTD Drug ID: DMOSTXF

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3-kinase gamma (PIK3CG)	TTHBTOP	PK3CG_HUMAN	Modulator	[3]
Polo-like kinase 1 (PLK1)	TTIYVQP	PLK1_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Polo-like kinase 1 (PLK1)	DTT	PLK1	4.492	5.573	4.555	2.459

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Myelodysplastic syndrome

ICD Disease Classification

2A37

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
PI3-kinase gamma (PIK3CG)	DTT	PIK3CG	1.98E-01	-0.05	-0.55

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7833).
3	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.